Increasing FDA Approval for Drug-Eluting Stent Fuel the Market Growth

The global drug-eluting stent market is anticipated to grow at a considerable CAGR of 7.6% during the forecast period (2024-2031). The market growth is attributed to the expanding trend in FDA approvals. As the regulatory body grants more approvals for such stents, it indicates increased acceptance and trust in the safety and efficacy of drug-eluting stents. This positive regulatory environment encourages innovation and investment in the development of new drug-eluting stent technologies. As a result, manufacturers are expanding their opportunities and market share, with healthcare providers and patients benefiting from a broader range of FDA-approved options for treating coronary artery disease. 

Browse the full report description of “Drug-eluting Stent Market Size, Share & Trends Analysis Report by material (Stainless Steel, Cobalt-Chromium Alloy, and Others), By Type, (Permanent and Biodegradable), By Application (Coronary Artery Stenting and Peripheral Artery Stenting), and by End-User (Hospitals and Cardiac Catheterization Laboratories), Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/drug-eluting-stent-market

• In October 2023, Medinol Ltd., obtained FDA approval for its EluNIR-PERL drug-eluting stent (DES) system to treat coronary artery disease. The stent, part of the EluNIR family, featured four radiopaque markers for enhanced visualization during procedures, aiding navigation through complex anatomies and precise stent placement. 

• In May 2022, Medtronic received FDA approval for Onyx Frontier™ drug-eluting stent, part of the resolute DES family. It utilized the Resolute Onyx™ DES stent platform with an improved delivery system for enhanced deliverability and acute performance in challenging cases. 

• In June 2021, Abbott Laboratories’ XIENCE stents secured FDA approval for one-month DAPT labeling in high bleeding risk patients in the US, with CE Mark approval for the same globally. Additionally, FDA and CE Mark approval was granted for the next-gen XIENCE Skypoint stent, offering improved placement and enhanced expansion for treating larger blood vessels. 

• In September 2021, BIOTRONIK SE & Co KG received US FDA approval for its Orsiro® Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The Orsiro Mission DES featured a stent design and bioabsorbable coating with controlled drugs. 

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Material

o By Type

o By Application

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- include Abbott Laboratories, Boston Scientific Corp., Biotronik SE & Co. KG, Medtronic Plc, Terumo Corp., and others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Drug-Eluting Stent Market Report Segment

By Material

• Stainless Steel 
• Cobalt-Chromium Alloy
• Others (Platinum-Chromium Alloy)

By Type

• Permanent 
• Biodegradable

By Application

• Coronary Artery Stenting
• Peripheral Artery Stenting

By End-user

• Hospitals
• Cardiac Catheterization Laboratories

Global Drug-Eluting Stent Market Report Segment by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/drug-eluting-stent-market